Diaceutics and London Genetics Partner to Accelerate Biomarker Development in the Global Biopharmaceutical Industry

WASHINGTON and LONDON, September 15, 2010 - Diaceutics Limited (www.diaceutics.com) and London Genetics
Limited, an expert in the use of pharmacogenetics in clinical drug discovery
and development, today announce a strategic partnership to develop software
decision tools that will provide biopharmaceutical companies with rapid and
extensive access to the world's leading academic biomarker research groups.
The new tools will enable commercial biomarker research teams to
comprehensively explore global biomarker resources to identify genes and gene
sequences, as well as the researchers and clinicians relevant to their
targeted therapy research.

The new software, which is expected to be launched in 2011, is based on
the Diaceutics Fusion platform, the leading personalised medicine planning
software application for targeted therapy development teams, and the London
Genetics Biomarker Pathway platform. The tools to be developed under the
strategic partnership will allow research teams to build biomarker
hypotheses, request expressions of interest and prepare proposals for
clinical development. The expressions of interest, requesting access to
patient samples and investigator networks, will be sent to academic biomarker
research teams globally, including London Genetics' own network of over 3,000
investigators in a broad range of therapeutic areas and technology
disciplines. In this way, partners can be rapidly identified and
collaborative projects instigated.

"We are delighted to partner with London Genetics, leverage their
biomarker expertise, and together build tools that will address a key problem
for therapy development teams," said Peter Keeling, CEO of Diaceutics.
"Biomarker research is often limited because teams don't know the
capabilities of external research centers and miss potential collaborations
which could accelerate their targeted therapy development."

"This strategic alliance with Diaceutics fits closely with our overall
goal to expedite pharmacogenetic and biomarker partnerships between industry
and academia for more effective targeted drug development," said Dominique
Kleyn, CEO of London Genetics. "We look forward to working with new industry
partners identified via the tools we are developing with Diaceutics."

Notes to Editors:

About London Genetics

London Genetics Limited, a not-for-profit company, is an expert in the
use of pharmacogenetics in clinical drug discovery and development.
Established in 2007 with funding from the London Development Agency, its
seven founding partners are leading London academic and medical institutions
with clinical and genetic expertise and significant patient resources. The
company provides pharmaceutical and biotechnology companies with access to
this expertise and resource, as well as providing strategic advice on the
application of pharmacogenetics for successful drug development. LGL has
broad therapeutic expertise, based on its access to 3,000 academic groups
with a GBP650m annual research spend. Recent agreements developed by London
Genetics include a collaboration between the International Serious Adverse
Events Consortium, St George's University of London and the Drug Safety
Research Unit at Southampton, UK. LGL is based in central London and has ISO
9001 accreditation. For further information, please go to
www.londongenetics.com

About Diaceutics:

About Diaceutics: Diaceutics is an international change management and
consulting firm specializing in personalized medicine. Diaceutics mission is
to build bridges between pharmaceutical and diagnostic companies and to
provide pharmaceutical industry leaders with the foundation and operational
structure necessary to effectively develop and commercialize targeted
therapies that better meet patients' needs and improve return on investment.
For more information, visit www.diaceutics.com.Diaceutics is an
international change management and consulting firm specializing in
personalized medicine. Diaceutics mission is to build bridges between
pharmaceutical and diagnostic companies and to provide pharmaceutical
industry leaders with the foundation and operational structure necessary to
effectively develop and commercialize targeted therapies that better meet
patients' needs and improve return on investment. For more information, visit
www.diaceutics.com.

About Pharmacogenetics:

Genetic differences between individuals mean that drug response rates are
often variable across a population, and this has significant implications for
healthcare cost effectiveness. Pharmocogenetics, the study of the clinical
consequences of genetic differences in the way people metabolise and respond
to drugs, is expected to generate better understanding of how drugs work in
the body, and therefore give insight into how to develop more efficacious and
safer drugs. It also has implications for product life cycle management and
the revitalisation of drugs which previously failed in clinical trials. With
drug development costs rising and R&D productivity falling, plus increased
regulator focus on safety and cost-effectiveness, pharmacogenetics is
expected to become increasingly important in drug development. The FDA and
the EMA have recognised this in their Critical Path Initiative and Road Map
respectively.

    Contact for London Genetics Ltd:
    Dominique Kleyn, CEO,
    +44-(0)207-594-1838

    Emma Palmer Foster, Strategic Communications Consultant,
    +44-(0)7880-787-185
    communications@londongenetics.com

    Contact for Diaceutics:
    Mollie Roth, Esq.,
    Chief Operating Officer
    +1-202-280-5887
    mollie.roth@diaceutics.com

Contact for London Genetics Ltd: Dominique Kleyn, CEO, +44-(0)207-594-1838, Emma Palmer Foster, Strategic Communications Consultant, +44-(0)7880-787-185, communications at londongenetics.com . Contact for Diaceutics: Mollie Roth, Esq., Chief Operating Officer, +1-202-280-5887, mollie.roth at diaceutics.com